Therapeutic vaccination against HSV-2: Influence of vaccine formulation on immune responses and protection in mice

Vaccine

Volumn 18, Issue 17, 2000, Pages 1778-1792

  Mohamedi, S A ^a   Heath, A W ^a   Jennings, R ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Genital herpes; Interferon gamma; Interleukin 4; ISCOMs; Therapeutic immunisation

Indexed keywords

ALUMINUM POTASSIUM SULFATE; GAMMA INTERFERON; HERPES SIMPLEX VACCINE; INTERLEUKIN 2; INTERLEUKIN 4; ISCOM; QUIL A;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG FORMULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENITAL HERPES; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HERPES VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOMODULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEROLOGY; SPLEEN CELL; TH1 CELL; TH2 CELL; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, VIRAL; FEMALE; HERPES GENITALIS; HERPESVIRUS 1, HUMAN; HERPESVIRUS 2, HUMAN; IMMUNITY, CELLULAR; IMMUNOGLOBULIN G; INJECTIONS, INTRAPERITONEAL; INTERFERON TYPE II; INTERLEUKIN-2; INTERLEUKIN-4; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; NEUTRALIZATION TESTS; SPLEEN; TH1 CELLS; TH2 CELLS; VACCINES, ATTENUATED; VIRAL VACCINES;

EID: 0034004314     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(99)00483-1     Document Type: Article

References (58)

1. Henken D.B., Goldstein M.E., Martin J.R. Herpes simplex virus type-2 infection by a footpad route results in neuronal death in mouse spinal ganglia. J. Neurol. Sci. 115:1993;177.
2. Corey L., Spear P.G. Infections with herpes simplex viruses. New. Eng. J. Med. 314:1986;386.
3. Whitley R.J., Kimberlin D.W., Roizman B. Herpes simplex viruses. Clin. Infect. Dis. 26:1998;541.
4. Hook E.W. III, Cannon R.O., Nahmias A.J. Herpes simplex virus infection as a risk factor for human immunodeficiency virus infection in heterosexuals. J. Infec. Dis. 165:1992;251.
5. Gwanzura L., McFarland W., Alexander D., Burke R.L., Katzenstein D. Association between human immunodeficiency virus and herpes simplex virus type 2 seropositivity among male factory workers in Zimbabwe. J. Infect. Dis. 177:1998;481.
6. Frank S.B. Formolized herpes virus therapy and the neutralising substance in herpes simplex. J. Invest. Dermatol. 1:1938;267.
7. Straus S.E., Savarese B., Tigges M.A., Freifeld A.G., Krause P.R., Margolis D.M., Meier J.L., Paar D.P., Adair S.F., Dina D., Dekker C., Burke R.L. Induction and enhancement of immune responses to herpes simplex virus type 2 in humans with a recombinant glycoprotein D vaccine. J. Infect. Dis. 167:1993;1045.
8. Straus S.E., Corey L., Burke R.L., Savarese B., Barnum G., Krause P.R., Kost R.G., Meier J.L., Sekulovich R., Adair S.F., Dekker C.L. Placebo-controlled trial of vaccination with recombinant glycoprotein D of herpes simplex virus type 2 for immuno-therapy of genital herpes. Lancet. 343:1994;1460.
9. Stanberry L.R. Herpes immunisation - on the threshold. J. Eur. Acad. Dermatol. Venereol. 7:1996;120.
10. Rinaldo C.R., Torpey D.J. III. Cell-mediated immunity and immunosuppression in herpes simplex virus infection. Immunodeficiency. 5:1993;33.
11. Carmack M.A., Yasukawa L.L., Hang S.Y., Tran C., Saldana F., Arvin A.M., Prober C.G. T-cell recognition and cytokine production elicited by common and type specific glycoproteins of herpes simplex virus type 1 and type 2. J. Infect. Dis. 194:1996;899.
12. + cytotoxic T-lymphocyte precursors specific for herpes simplex viruses in persons with genital herpes. J. Virol. 70:1996;8165.
13. Mikloska Z., Cunningham A.L. Herpes simplex virus type 1 glycoproteins gB, gC and gD are major targets for CD4 T-lymphocyte cytotoxicity in HLA-DR expressing human epidermal keratinocytes. J. Gen. Virol. 79:1998;353.
14. + cytotoxic T lymphocyte activity. Proc. Natl. Acad. Sci. USA. 94:1997;10289.
15. Posavad C.M., Koelle D.M., Corey L. Tipping the scales of herpes simplex virus reactivation: The important responses are local. Nature Med. 4:1998;381.
16. Mossman T.R., Sad S. The expanding universe of T-cell subsets, Th1, Th2 and more. Imm. Today. 17:1996;138.
17. Coffman R.L., von der Weid T. Multiple pathways for the inititation of T helper 2 (Th2) responses. J. Exp. Med. 185:1997;373.
18. Clerici M., Shearer G.M. A Th1 to Th2 switch is a critical step in the etiology of HIV infection. Imm. Today. 14:1993;107.
19. Fischer J.E., Johnson J.E., Kuli-Zade R.K., Johnson T.R., Aung S., Parker R.A., Graham B.S. Overexpression of interleukin-4 delays virus clearance in mice infected with respiratory syncytial virus. J. Virol. 71:1997;8672.
20. + T helper type 2 T lymphocytes do not promote recovery from experimental virus infection. J. Exp. Med. 180:1994;1273.
21. Torseth W., Merigan T.C. Significance of local γ-interferon in recurrent herpes simplex virus infection. J. Infect. Dis. 153:1986;979.
22. Spruance S, McKeough M, Evans T, Mishkin E, Abramovitz A. 1993. Correlation between a history of herpes labialis, experimental radiation (UVR)-induced herpes labialis, neutralising antibody (NEUTAB) and IL-2 and γ-IFN production by PBMC. 33rd ICAAC Meeting (Abstract).
23. Koelle D.M., Posavad C.M., Barnum G.R., Johnson M.L., Frank J.M., Corey L. Clearance of HSV-2 from recurrent genital lesions correlates with infiltration of HSV-specific cytotoxic T lymphocytes. J. Clin. Invest. 101:1998;1500.
24. Ghiasi H., Roopenian D.C., Slanina S., Cai S., Nesburn A.B., Wechsler S. The importance of MHC-I and MHC-II responses in vaccine efficacy against herpes simplex virus type I challenge. Immunology. 91:1997;430.
25. Tang Y., Neuzil K.M., Fischer J.E., Robinson F.W., Parker R.A., Graham B.S. Determinants and kinetics of cytokine expressed patterns in lungs of vaccinated mice challenged with respiratory syncytial virus. Vaccine. 15:1997;597.
26. Tomoda T., Morita H., Kurashige T., Maassab H.F. Prevention of influenza by the intranasal administration of cold-recombinant, live-attenuated influenza virus vaccine: importance of interferon-γproduction and local IgA production. Vaccine. 13:1995;185.
27. Gorse G.J., Campbell M.J., Otto E.E., Powers D.C., Chambers G.W., Newman F.K. Increased anti-influenza A virus cytotoxic T cell activity following vaccination of the chronically ill elderly with live attenuated or inactivated influenza virus vaccine. J. Inf. Dis. 172:1995;1.
28. Nguyen L.H., Knipe D.M., Finberg R.W. Replication-defective mutants of herpes simplex virus (HSV) induce cellular immunity and protect against lethal HSV infection. J. Virol. 66:1992;7067.
29. Nguyen L., Knipe D.M., Finberg R.W. Mechanisms of virus-induced Ig subclass shifts. J. Immunol. 152:1994;478.
30. McLean C.S., Ní Challanáin D., Duncan I., Bournsell M.E.G., Jennings R., Inglis S.C. Induction of a protective immune response by mucosal vaccination with a DISC HSV-1 vaccine. Vaccine. 14:1996;987.
31. Walker J., Leib D.A. Protection from primary infection and establishment of latency by vaccination with a herpes simplex virus type 1 recombinant deficient in the virion host shut-off (vhs) function. Vaccine. 16:1998;1.
32. Geerligs H.J., Weijer W.J., Welling G.W., Welling-Wester S. The influence of different adjuvants on the immune response to a synthetic peptide comprising amino acid residues 9-21 of herpes simplex virus type 1 glycoprotein D. J. Immunol. Meth. 124:1989;95.
33. Clerici M., Tacket C.O., Via C.S., Lucey D.R., Muluk S.C., Zajac R.A., et al. Immunisation with subunit human immunodeficiency virus vaccine generates stronger T helper cell immunity than natural infection. Eur. J. Immunol. 21:1991;1345.
34. York L.J., Giorgio D.P., Mishkin E.M. Immunomodulatory effects of HSV-2 glycoprotein D in HSV-1 infected mice; implication for immunotherapy of recurrent HSV infection. Vaccine. 13:1995;1706.
35. Morein B., Sundquist B., Hoglund S., Dalsgaard K., Osterhaus A. ISCOM, a novel structure for antigenic presentation of membrane proteins from enveloped viruses. Nature. 308:1984;457.
36. + cytotoxic T cells by immunisation with purified HIV-1 envelope proteins in ISCOMs. Nature. 344:1990;873.
37. Villacress-Erikson M., Bergstrom-Mollauglu M., Kaberg H., Morein B. Involvement of IL-2 and IFN-γ in the immune response induced by influenza virus ISCOMs. Scand. J. Immunol. 36:1992;421.
38. Hassan Y., Brewer J.M., Alexander J., Jennings R. Immune responses in mice induced by HSV-1 glycoproteins presented with ISCOMs or NISV delivery systems. Vaccine. 14:1996;1581.
39. Sjolander A., van't Land B., Bengtsson K.V. ISCOMs containing purified Quillaja saponins up-regulate both Th1-like and Th2-like immune responses. Cell Immunol. 177:1997;69.
40. Erturk M., Hill T.J., Shimeld C.A., Jennings R. Acute and latent infections of mice immunised with HSV-1 ISCOM vaccine. Arch. Virol. 125:1992;87.
41. Bournsell M.E.G., Entwisle C., Blakeley D., Roberts C., Duncan I.A., Chisholm S.E., Martin G.M., Jennings R., Ní Challanáin D., Sobek I., Inglis S.C., McLean C.S. A genetically inactivated herpes simplex virus type 2 (HSV-2) vaccine provides effective protection against primary and recurrent HSV-2 disease. J. Infect. Dis. 175:1997;16.
42. Erturk M., Jennings R., Phillpotts R.J., Potter C.W. Biochemical characterisation of herpes simplex virus type 1 immunostimulating complexes (ISCOMs): a multi-glycoprotein structure. Vaccine. 9:1991;668.
43. Farrell H.E., McLean C.S., Harley C., Efstathiou S., Inglis S.C., Minson A.C. Vaccine potential of a herpes simplex virus type 1 mutant with an essential glycoprotein deleted. J. Virol. 68:1994;927.
44. Mathiesen T., Perssons M.A.A., Sundquist V.A., Wahren B. Neutralisation capacity and antibody dependent cell-mediated cytotoxicity of separated IgG subclass 1, 3 and 4 against herpes simplex virus. J. Clin. Exp. Immunol. 72:1988;211.
45. Irie H., Shimeld C., Williams N., Hill T. Protection against ocular and cutaneous infection with herpes simplex virus type 1 by intragastric immunisation with live virus. J. Gen. Virol. 74:1993;1357.
46. Mark A., Bjorksten B., Granstrom M. Immunoglobulin E responses to diphtheria and tetanus toxoids after booster with aluminium-adsorbed and fluid DT-vaccines. Vaccine. 13:1995;669.
47. Fast D.J., Vosika G.J. The muramyl dipeptide analog GMTP-N-DPG preferentially induces cellular immunity to soluble antigens. Vaccine. 15:1997;1748.
48. Mellado M., Llorente M., Rodríguez-Frade J.M., Luca P., Martinez-A C., del Real G. HIV-1 envelope protein gp 120 triggers a Th2 response in mice that shifts to Th1 in the presence of human growth hormone. Vaccine. 15:1998;1111.
49. Baca-Estrada M.E., Foldvari M., Snider M., van Drunen den Littel.-van Hurk S., Babuik L.A. Effect of IL-4 and IL-12 liposomal formulations on the induction of immune responses to bovine herpesvirus type-1 glycoprotein D. Vaccine. 15:1997;1753.
50. Prayaga S.K., Ford M.J., Haynes J.R. Manipulation of HIV-1 gp 120-specific immune responses elicicted via gene gun-based DNA immunisation. Vaccine. 15:1997;1349.
51. + T cell subsets in the regulation of parasite immunity and disease. Imm. Revs. 112:1989;161.
52. Stanberry L.R. Herpes simplex virus vaccines as immunotherapeutic agents. Trends Microbiol. 3:1995;244.
53. Burke R.L. Current developments in herpes simplex virus vaccines. Sem. Virol. 4:1993;187.
54. Jayaraman S., Heiligenhaus A., Rodriguez A., Soukiasian S., Dorf M.E., Foster S.C. Exacerbation of murine herpes simplex virus-mediated stromal keratitis by Th2 type T cells. J. Immunol. 151:1993;5777.
55. Barr I.G., Mitchell G.F. ISCOMs (immunostimulating complexes): The first decade. Immunol. Cell Biol. 74:1996;8.
56. Jennings R., Simms J.R., Heath A.W. Adjuvants and delivery systems for viral vaccines - mechanisms and potential. Dev. Biol. Stand. 92:1998;19.
57. Romagnani S. Human Th1 and Th2 subsets: regulation of differentiation and role in protection and immunopathology. Int. Arch. All. Immunol. 98:1992;279.
58. Graham B.S., Henderson G.S., Tang Y.-W., Lu X., Neuzil K.M., Colley D.C. Priming immunisation determines T helper cytokine mRNA expression patterns in lungs of mice challenged with respiratory syncytial virus. J. Immunol. 151:1993;2032.